XML 45 R39.htm IDEA: XBRL DOCUMENT v3.25.3

Segments (Tables)

9 Months Ended

Sep. 30, 2025

Summary of Segment Profit

a. Segment information:

		Three months ended September 30,
		2025
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,483			$	1,235			$	557
Cost of sales			996				570				280
R&D expenses			161				62				26
S&M expenses			278				225				122
G&A expenses			114				75				36
Other			(3	)			§				§
Segment profit		$	937			$	303			$	95

§ Represents an amount less than $0.5 million. 

		Three months ended September 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	2,225			$	1,265			$	613
Cost of sales			960				566				307
R&D expenses			151				55				27
S&M expenses			259				203				134
G&A expenses			107				67				36
Other			§				1				§
Segment profit		$	748			$	373			$	109

§ Represents an amount less than $0.5 million. 

		Nine months ended September 30,
		2025
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	6,543			$	3,726			$	1,634
Cost of sales			2,748				1,687				835
R&D expenses			467				181				75
S&M expenses			831				652				353
G&A expenses			323				210				107
Other			(1	)			§				(3	)
Segment profit		$	2,175			$	996			$	266

§ Represents an amount less than $0.5 million.

		Nine months ended September 30,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	6,060			$	3,749			$	1,802
Cost of sales			2,769				1,637				914
R&D expenses			475				173				85
S&M expenses			789				605				397
G&A expenses			300				197				109
Other			(1	)			1				(1	)
Segment profit		$	1,727			$	1,137			$	299

The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended September 30, 2025 and 2024:

		Three months ended								Nine months ended
		September 30,								September 30,
		2025				2024				2025				2024
		(U.S. $ in millions)								(U.S. $ in millions)
United States profit		$	937			$	748			$	2,175			$	1,727
Europe profit			303				373				996				1,137
International Markets profit			95				109				266				299
Total reportable segments profit			1,334				1,230				3,437				3,163
Profit (loss) of other activities			(40	)			(16	)			(64	)			(1	)
Amounts not allocated to segments:
Amortization			144				146				436				444
Other assets impairments, restructuring and other items			62				(23	)			272				931
Goodwill impairment			—				600				—				1,000
Intangible assets impairments			64				28				227				169
Legal settlements and loss contingencies			60				450				309				638
Other unallocated amounts			82				64				272				254
Consolidated operating income (loss)			882				(51	)			1,857				(274	)
Financial expenses, net			237				272				714				763
Consolidated income (loss) before income taxes		$	646			$	(324	)		$	1,143			$	(1,037	)

Schedule Of Consolidated Income Before Income Tax

b. Segment revenues by major products and activities:

The following tables present revenues by major products and activities for the three months ended September 30, 2025 and 2024:

United States		Three months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including biosimilars)		$	1,175			$	1,094
AJOVY®			73				58
AUSTEDO			601				435
BENDEKA® and TREANDA®			35				40
COPAXONE			62				69
UZEDY			43				35
Anda			392				380
Other			101				115
Total		$	2,483			$	2,225

United States		Nine months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including biosimilars)		$	2,984			$	2,924
AJOVY			190				144
AUSTEDO			1,492				1,124
BENDEKA and TREANDA			111				127
COPAXONE			179				179
UZEDY			136				75
Anda			1,130				1,134
Other			321				352
Total		$	6,543			$	6,060

Europe		Three months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	982			$	973
AJOVY			66				56
COPAXONE			44				53
Respiratory products			52				60
Other*			91				124
Total		$	1,235			$	1,265

* Other revenues in the third quarter of 2025 and 2024 include the sale of certain product rights.

Europe		Nine months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	3,011			$	2,947
AJOVY			195				158
COPAXONE			135				163
Respiratory products			162				183
Other*			223				299
Total		$	3,726			$	3,749

* Other revenues in the first nine months of 2025 and 2024 include the sale of certain product rights.

International markets		Three months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	421			$	477
AJOVY			30				24
AUSTEDO			17				13
COPAXONE			8				13
Other*			82				86
Total		$	557			$	613

* Other revenues in the third quarter of 2025 and 2024 include the sale of certain product rights.

International markets		Nine months ended September 30,
		2025				2024
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	1,298			$	1,440
AJOVY			78				63
AUSTEDO			34				39
COPAXONE			25				38
Other*			199				222
Total		$	1,634			$	1,802

* Other revenues in the first nine months of 2025 and 2024 include the sale of certain product rights.

X

- Definition

Schedule of consolidated income before income tax.

+ References

No definition available.

+ Details

Name:	teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration